Bright Minds Biosciences Inc (DRUG)

$42.97 +0.73 (1.73%)
Market Cap 297.54M
Revenue (ttm) 0.00
Net Income (ttm) -2.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 99,000
Avg Vol 65,358
Day's Range N/A - N/A
Shares Out 7.04M
Stochastic %K 59%
Beta -6.14
Analysts Strong Sell
Price Target $83.25

Company Profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indicatio...

Industry: Biotechnology
Sector: Healthcare
Phone: 647 865 8622
Address:
19 Vestry Street, New York, United States
canievas
canievas Sep. 8 at 11:50 PM
$BCDA BUY AND HOLD SHE WILL RUN LIKE $DRUG AND $OCTO WHEN THE TIME ITS RIGHT. 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
Timetoflytodamoon
Timetoflytodamoon Sep. 8 at 9:06 PM
$HOLO it's going to be like $DRUG back in OCT2024 and $OCTO today. "to endure a delay, difficulty, or tedious situation with calmness, composure, and without anger or frustration"
1 · Reply
simplifocused
simplifocused Sep. 8 at 3:23 PM
$KAPA I hope this will pull anorher $DRUG move or $OCTO moves NFA
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 8 at 1:31 PM
$OCTO I remember when $DRUG used to run from the same levels... and it went up to 72$
0 · Reply
Quantumup
Quantumup Sep. 8 at 11:14 AM
BTIG🏁 $DRUG Buy/$72. LBPH - $HLUBF/ $HLBBF $UCBJY $PRAX BTIG said in its initiation report: Bright Minds Biosciences ( $DRUG, Buy, $72 PT) is developing a very specific 5-HT2C agonist for epilepsies that is widely viewed as Longboard-like, but with key points of differentiation. BTIG added:
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 10:30 AM
BTIG updates rating for Bright Minds Biosciences ( $DRUG ) to Buy, target set at 72.
0 · Reply
DARKP00L
DARKP00L Sep. 8 at 10:22 AM
$DRUG 06:10 on Sep. 08 2025 BTIG Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $72 #tradeideas
0 · Reply
xyz_consulting
xyz_consulting Sep. 7 at 4:35 AM
$DRUG time to sell
0 · Reply
Jusar
Jusar Sep. 5 at 12:27 AM
$DRUG at least they are taking advantage of the higher price when they do the ATM.
1 · Reply
StockfatherOG
StockfatherOG Sep. 4 at 11:24 PM
$HOUR no shares to borrow and if you look at the volume today - 9M compared to the 1M float you will realize that tons of naked shorts are trapped as well. This is how true squeezes like $DRUG started back when it ran from $2 to around $100…
1 · Reply
Latest News on DRUG
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

May 20, 2025, 8:00 AM EDT - 3 months ago

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

May 7, 2025, 4:45 PM EDT - 4 months ago

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Apr 28, 2025, 8:00 AM EDT - 4 months ago

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Apr 16, 2025, 12:09 PM EDT - 5 months ago

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101

Jan 26, 2025, 6:32 AM EST - 8 months ago

Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Jan 7, 2025, 6:50 AM EST - 8 months ago

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Nov 4, 2024, 2:41 PM EST - 11 months ago

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential

Oct 30, 2024, 1:07 AM EDT - 11 months ago

Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Oct 28, 2024, 8:21 AM EDT - 11 months ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

NVCT

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Oct 21, 2024, 8:30 AM EDT - 11 months ago

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Oct 18, 2024, 6:50 AM EDT - 11 months ago

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Oct 16, 2024, 10:45 AM EDT - 11 months ago

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Bright Minds is Unaware of Any Material Changes

Oct 15, 2024, 9:09 PM EDT - 11 months ago

Bright Minds is Unaware of Any Material Changes

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

Oct 3, 2024, 9:00 AM EDT - 1 year ago

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Sep 19, 2024, 10:00 AM EDT - 1 year ago

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Aug 8, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 20, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

Jul 12, 2023, 10:33 AM EDT - 2 years ago

CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

Bright Minds Announces Effective Date of Share Consolidation

Jul 11, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Announces Effective Date of Share Consolidation

Bright Minds Announces Proposed Share Consolidation

Jun 22, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Announces Proposed Share Consolidation

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Apr 19, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Apr 10, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Feb 27, 2023, 6:50 AM EST - 2 years ago

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Bright Minds Biosciences Announces Non-Executive Director Appointment

Feb 17, 2023, 6:50 AM EST - 2 years ago

Bright Minds Biosciences Announces Non-Executive Director Appointment

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Feb 8, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Jan 27, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Bright Minds Biosciences Announces Resignation of Board Member

Jan 9, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Resignation of Board Member

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Dec 2, 2022, 7:07 PM EST - 3 years ago

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Bright Minds Biosciences Announces Non-Brokered Private Placement

Nov 28, 2022, 6:50 AM EST - 3 years ago

Bright Minds Biosciences Announces Non-Brokered Private Placement

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.

Nov 23, 2022, 11:35 AM EST - 3 years ago

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Sep 7, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Aug 31, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Aug 30, 2022, 3:35 PM EDT - 3 years ago

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Bright Minds Announces Pricing of Overnight Marketed Offering of Units

Aug 23, 2022, 9:07 PM EDT - 3 years ago

Bright Minds Announces Pricing of Overnight Marketed Offering of Units

Bright Minds Announces Overnight Marketed Offering of Units

Aug 22, 2022, 7:05 PM EDT - 3 years ago

Bright Minds Announces Overnight Marketed Offering of Units

Bright Minds Biosciences Comments on Recent Trading Activity

Aug 18, 2022, 3:34 PM EDT - 3 years ago

Bright Minds Biosciences Comments on Recent Trading Activity

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

Jun 27, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

May 12, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

May 2, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Nov 30, 2021, 7:30 AM EST - 4 years ago

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq

Nov 4, 2021, 8:52 AM EDT - 4 years ago

Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

Nov 3, 2021, 6:50 AM EDT - 4 years ago

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

canievas
canievas Sep. 8 at 11:50 PM
$BCDA BUY AND HOLD SHE WILL RUN LIKE $DRUG AND $OCTO WHEN THE TIME ITS RIGHT. 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
Timetoflytodamoon
Timetoflytodamoon Sep. 8 at 9:06 PM
$HOLO it's going to be like $DRUG back in OCT2024 and $OCTO today. "to endure a delay, difficulty, or tedious situation with calmness, composure, and without anger or frustration"
1 · Reply
simplifocused
simplifocused Sep. 8 at 3:23 PM
$KAPA I hope this will pull anorher $DRUG move or $OCTO moves NFA
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 8 at 1:31 PM
$OCTO I remember when $DRUG used to run from the same levels... and it went up to 72$
0 · Reply
Quantumup
Quantumup Sep. 8 at 11:14 AM
BTIG🏁 $DRUG Buy/$72. LBPH - $HLUBF/ $HLBBF $UCBJY $PRAX BTIG said in its initiation report: Bright Minds Biosciences ( $DRUG, Buy, $72 PT) is developing a very specific 5-HT2C agonist for epilepsies that is widely viewed as Longboard-like, but with key points of differentiation. BTIG added:
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 10:30 AM
BTIG updates rating for Bright Minds Biosciences ( $DRUG ) to Buy, target set at 72.
0 · Reply
DARKP00L
DARKP00L Sep. 8 at 10:22 AM
$DRUG 06:10 on Sep. 08 2025 BTIG Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $72 #tradeideas
0 · Reply
xyz_consulting
xyz_consulting Sep. 7 at 4:35 AM
$DRUG time to sell
0 · Reply
Jusar
Jusar Sep. 5 at 12:27 AM
$DRUG at least they are taking advantage of the higher price when they do the ATM.
1 · Reply
StockfatherOG
StockfatherOG Sep. 4 at 11:24 PM
$HOUR no shares to borrow and if you look at the volume today - 9M compared to the 1M float you will realize that tons of naked shorts are trapped as well. This is how true squeezes like $DRUG started back when it ran from $2 to around $100…
1 · Reply
prismmarketview
prismmarketview Sep. 4 at 4:59 PM
(NASDAQ: $DRUG) #brightmindsbioscience reports that BMB‑201, a non-hallucinogenic 5‑HT2A/2C agonist, outperforms sumatriptan in a rat vascular headache model—showing stronger pain relief across multiple timepoints in both sexes. A promising leap forward in non‑opioid pain therapies. https://prismmarketview.com/bright-minds-biosciences-reports-positive-preclinical-data-for-bmb-201-in-pain-models/
0 · Reply
squiggleburp
squiggleburp Sep. 4 at 3:17 PM
$ABVE $OPEN $IPDN $IXHL Can I get an amen!! In addition to a massive merger that will be coming down the pipe ABVE is clearly branching out. Huge press release, muted response means once this gets eyes, we will be heading North with conviction. I encourage yall to have a look at what Wall Street is calling” an opportunity to rip the tip and leave the pink behind”! If that ain’t proof of a stock that will repeat the rally we witnessed in $DRUG I don’t know what is! BURP! Did someone say drugs? Mmmmmmm! Have a look 👇
1 · Reply
theflynews
theflynews Sep. 4 at 3:15 PM
Psychedelic: Bright Minds reports preclinical BMB-201 results - $DRUG - https://thefly.com/permalinks/entry.php/DRUGid4193212?1756998281C38
0 · Reply
Noideawhatimdoing23
Noideawhatimdoing23 Sep. 4 at 3:14 PM
$ASST no doubt this is the next $DRUG and we only have 3 trading days until our catalyst drops. That being said, the shorts will use every possible angle they can to suppress this. This isn’t just a squeeze, this is a legendary squeeze building and will explode in T-3 days at the latest.
0 · Reply
CryptoSenderX
CryptoSenderX Sep. 4 at 2:10 PM
$ALBT the next $RGC I $DRUG I $SOGP is ready 🪐
0 · Reply
canievas
canievas Sep. 3 at 7:28 PM
$BCDA SHE WILL RUN LIKE $DRUG REMEMBER FROM $2 TO ALMOST $50
0 · Reply
Takeover24
Takeover24 Sep. 2 at 6:23 PM
$CLNN Could this be the next $DRUG or $MNPR?
0 · Reply
AimTitan
AimTitan Sep. 1 at 3:42 PM
$RMLFF Rusoro to get $1.6bn!!!! $SERV $TTEC $DRUG $LAC https://www.reuters.com/business/energy/elliott-affiliates-589-billion-bid-recommended-winner-citgo-auction-2025-08-30/
0 · Reply
Thorilium
Thorilium Aug. 30 at 2:50 PM
$ICU this could be a new $DRUG kinda graph, hold down
2 · Reply
Doozio
Doozio Aug. 28 at 8:31 PM
$XBI some wud say $DRUG zzzz are good for yo $IQ during 🐒🍌🧠⏰♾️
1 · Reply
kubota2323
kubota2323 Aug. 28 at 7:26 PM
$DRUG $NEUP any takers ?
0 · Reply
biochirp
biochirp Aug. 28 at 6:16 PM
$DRUG https://www.tipranks.com/news/ratings/bright-minds-biosciences-advancing-breakthrough-epilepsy-treatment-with-bmb-101-and-strong-financial-position-ratings PTs in the 100$+ range
0 · Reply